AI Article Synopsis
- Chronic myeloid leukemia (CML) is a cancer of blood stem cells caused by the BCR-ABL1 fusion protein, which results from a specific chromosomal translocation known as the Philadelphia chromosome.
- Monitoring patient outcomes in CML often involves quantitative real-time PCR to assess the presence of the BCR-ABL1 fusion.
- Targeting the BCR-ABL1 fusion kinase represents a groundbreaking approach in molecularly targeted therapies for effectively treating CML.
Article Abstract
Chronic myeloid leukemia (CML) is a hematological stem cell cancer driven by BCR-ABL1 fusion protein. We review the previous and recent evidence on the significance of CML in diagnostic and clinic management. The technical monitoring of with quantitative real time-PCR has been used in assessing patient outcome. The cytogenetic mark of CML is Philadelphia chromosome, that is formed by reciprocal chromosomal translocations between human chromosome 9 and 22, t(9:22) (q:q). It makes a BCR-ABL1 fusion protein with an anomaly tyrosine kinase activity that promotes the characteristic proliferation of progenitor cells in CML and acute lymphoblastic lymphoma. The targeting of BCR-ABL1 fusion kinase is the first novel paradigm of molecularly targeted curing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503218 | PMC |
| http://dx.doi.org/10.15430/JCP.2017.22.2.74 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!